Business Context and Reporting Period
This Form 8-K Current Report was filed by Cytomx Therapeutics, Inc. on March 29, 2017. The report discloses changes to the composition of the Company's Board of Directors, specifically the appointment of a new director and the resignation of an existing director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to director compensation: Marion McCourt received an option to purchase 28,000 shares of common stock with an exercise price of $17.00 per share.
Material Changes
- Appointment of Director: Marion McCourt was appointed to the Board of Directors effective March 29, 2017, as a Class III director. She was also appointed to the Compensation Committee.
- Resignation of Director: Dr. Timothy Shannon resigned from the Board and the Compensation Committee, effective March 30, 2017. The resignation is not due to any disagreement with the Company.
- Compensation Arrangement: Ms. McCourt received an option grant under the 2015 Equity Incentive Plan vesting monthly over 36 months, contingent on continued service.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding the Company's business operations or financial future. No specific risks or contingencies are disclosed in this report other than the standard indemnification agreement entered into with the new director.
Investor Verification Checklist
- Verify the biographical background and qualifications of the new director, Marion McCourt.
- Confirm the reason for Dr. Timothy Shannon's departure, noting the filing states it is not due to disagreement.
- Review the Company's Form 10-K/A filed on March 20, 2017, for details on the standard non-employee director compensation program.
- Check the press release filed as Exhibit 99.1 for additional context on the board changes.